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Integrin activation regulates adhesion, extracellular matrix assembly, and cell migration, thereby playing an indispensable 
role in development and in many pathological processes. A proline mutation in the central integrin β3 transmembrane 
domain (TMD) creates a flexible kink that uncouples the topology of the inner half of the TMD from the outer half. In this 
study, using leukocyte integrin α4β7, which enables development of gut-associated lymphoid tissue (GALT), we examined 
the biological effect of such a proline mutation and report that it impairs agonist-induced talin-mediated activation of 
integrin α4β7, thereby inhibiting rolling lymphocyte arrest, a key step in transmigration. Furthermore, the α4β7(L721P) 
mutation blocks lymphocyte homing to and development of the GALT. These studies show that impairing the ability of 
an integrin β TMD to transmit talin-induced TMD topology inhibits agonist-induced physiological integrin activation and 
biological function in development.
Transmission of integrin β7 transmembrane domain 
topology enables gut lymphoid tissue development
Hao Sun1, Frederic Lagarrigue1, Alexandre R. Gingras1, Zhichao Fan2, Klaus Ley2, and Mark H. Ginsberg1
Introduction
Regulation of the affinity of integrins for adhesive ligands is 
central to cell adhesion, migration, and assembly of the extra-
cellular matrix. Blood cells, such as leukocytes and platelets, have 
played a pivotal role in establishing current paradigms of this 
process because their integrins are expressed in a low-affinity 
form and intracellular signals initiated by agonists acting via dis-
tinct excitatory receptors, resulting in increased integrin affinity 
often referred to as “activation.” In these cells, talin binding to the 
integrin β2 or β3 cytoplasmic domains is a critical final common 
step in integrin activation both in vitro (Tadokoro et al., 2003; 
Shattil et al., 2010) and in vivo (Simonson et al., 2006; Nieswandt 
et al., 2007; Petrich et al., 2007a,b).
Mutational studies suggest that activation of integrin αΙΙbβ3 
requires disrupting interactions of the α and β cytoplasmic and 
transmembrane domains (TMDs; Hughes et al., 1996; Luo et al., 
2004). The αIIb and β3 TMD association is maintained by spe-
cific helical packing TMD interactions near the extracellular 
face of the membrane, termed the outer membrane clasp (Kim 
et al., 2009; Lau et al., 2009). Analyses of talin interactions 
with the β3 and β1D cytoplasmic domains (Wegener et al., 2007; 
Anthis et al., 2009) and molecular dynamic simulations (Kalli et 
al., 2011; Arcario and Tajkhorshid, 2014) suggest that talin dis-
rupts the outer membrane clasp by altering the topology of the 
β3 TMD. Work with isolated integrin TMD-cytoplasmic domain 
fragments in phospholipid nanodiscs provided direct experi-
mental evidence that talin binding can change the membrane 
embedding and therefore the topology of integrin β3 TMD 
(Kim et al., 2012).
Prolines perturb the structure of α helices by introducing a 
kink between the segments preceding and following the proline 
residue because of steric clash between the ring of the proline at 
position (i) and the backbone carbonyl at position (i-4). In addi-
tion, the lack of an amide proton also eliminates a helix backbone 
H-bond. The disruption of helical pattern and the reduction in 
H-bond stabilization lead to the flexibility of the kink in a pro-
line-containing transmembrane α helix (Woolfson and Williams, 
1990; von Heijne, 1991; Nilsson and von Heijne, 1998; Visiers et 
al., 2000). The structure of an integrin β3 TMD containing such 
a proline mutation [β3(A711P)], confirmed the expected flexible 
kink and showed that it prevents the transmission of talin-in-
duced change in β3 TMD topology across the membrane (Kim et 
al., 2011, 2012). The physiological importance of transmission of 
such topology changes through the integrin β TMD has not been 
tested nor has it been examined in integrins other than β3. The 
latter issue is particularly compelling in light of recent research 
stressing that mechanisms of integrin activation may differ 
markedly among different integrin classes (Lu et al., 2016).
We selected lymphocyte α4β7 to test the importance of 
talin-induced topology change because the role of its cytoplas-
mic domain in adhesion regulation has long been known (Crowe 
et al., 1994); however, there is little understanding of the mecha-
nism of the final steps in its activation or of transmission of the 
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signal across the membrane. α4β7 integrin plays a crucial role 
in lymphocyte trafficking to gastrointestinal mucosa by binding 
to its ligand, MAdCAM-1, which is displayed on endothelial cells 
in intestinal postcapillary venules (Berlin et al., 1995; Sun et al., 
2014), thereby enabling construction of the gut immune system 
(Wagner et al., 1996; Gorfu et al., 2009). Integrin α4β7 has there-
fore emerged as proven therapeutic target in diseases involving 
the gut immune system such as inflammatory bowel disease (IBD; 
Feagan et al., 2013; Sandborn et al., 2013; Cherry et al., 2015) and 
as a potential target in HIV-AIDS (Arthos et al., 2008; Byrareddy 
et al., 2016). Agonist stimulation, important in lymphocyte traf-
ficking to gut-associated lymphoid tissues (GALTs; Gorfu et al., 
2009; Sun et al., 2014), can activate integrin α4β7; however, direct 
proof of an integrin activation requirement by itself for devel-
opment is lacking. In this study, we report that talin binding to 
the β7 cytoplasmic domain activates α4β7 in a fashion analogous 
to αIIbβ3 and that creation of a flexible kink in the β7 TMD by 
insertion of proline, but not other mutations, impairs activation. 
We find that the β7(L721P) mutation prevents the activation of 
α4β7 by chemokine agonists, thereby inhibiting arrest of rolling 
lymphocytes in a flow chamber and their homing to GALT. More-
over, we report that GALT development is disrupted in a mouse 
bearing a β7(L720P) mutation. These studies show, for the first 
time, that impairing the ability of the integrin β TMD to transmit 
talin-induced TMD topology inhibits physiological integrin acti-
vation and biological functions in development.
Results
Talin binding to the β7 cytoplasmic domain 
activates integrin α4β7
Although it has long been known that agonists can activate T 
cell integrin α4β7 (Berlin et al., 1995), the role of talin in that 
process has not been evaluated. We used CRI SPR/Cas9 muta-
genesis to delete talin in Jurkat T cells, which lack endogenous 
β7 expression. Then, β7 was stably expressed in both Jurkat T 
cells and Jurkat T–talin knockout (KO) cells (Fig. 1 A). Addition 
of 12-O-tetradecanoylphorbol-13-acetate PMA failed to increase 
the low constitutive binding of soluble MAdCAM-1 to talin-null 
cells (Fig. 1 B), whereas the exogenous activator, Mn2+, stimu-
lated binding to talin-null cells. Talin deletion also abolished 
PMA-stimulated increase in firm adhesion of Jurkat-β7 cells on 
MAdCAM-1, confirming the loss of α4β7 activation (Fig. 1 C).
Talin binding to the integrin β3 cytoplasmic domain depends 
on engagement of the F3 subdomain of the talin FERM domain 
with a “membrane distal” site in the β3 tail (García-Alvarez et al., 
2003; Wegener et al., 2007). The β3(L746A) mutation selectively 
blocks talin binding, whereas β3(Y747A) blocks the binding of 
talin and other proteins (García-Alvarez et al., 2003; Petrich et 
al., 2007a; Haling et al., 2011). We aligned the β3 and β7 cytoplas-
mic tails and used that alignment to construct a homology model 
of β7 bound to the talin F3 domain (Fig. 1 D). The model predicted 
that β7 Leu758 and Tyr759 form critical hydrophobic contacts with 
talin F3, thereby fulfilling the role of β3 Leu746 and β3 Tyr747. The 
finding that β7(L758A) and β7(Y759A) mutations greatly reduced 
the binding of recombinant talin head domain (THD; Fig. S1, A 
and B) or full-length talin (Fig. S1 C) validated this model.
We then tested the effect of talin and integrin mutations 
in 293T cells because of technical ease of transfection. The β7 
mutants (Y759A or L758A) markedly inhibited the capacity of 
recombinant α4β7 to bind soluble MAdCAM-1 (Fig. 1 E). Expres-
sion of THD in these α4β7-expressing cells increased MAdCAM-1 
binding to α4β7; however, this increase was severely blunted by 
both β7 mutations (Fig. 1 E). The effects of these mutations on 
binding of soluble MAdCAM-1 were reflected in a marked reduc-
tion in cell adhesion to a MAdCAM-1 substrate (Fig.  1  F) and 
increase in rolling velocity (Fig. S1 D) at a wall shear stress of 2 
dyn/cm2 using a parallel wall flow chamber as described previ-
ously (Sun et al., 2014).
The homology model also indicated, similar to β3, that talin 
Leu325 and Trp359 would be important in the binding of talin to 
the membrane proximal helical segment and the membrane dis-
tal segment of the β7 tail, respectively. The β7–talin interaction 
was again similar to the β3–talin interaction (Wegener et al., 
2007) in that THD(W359A) showed negligible binding to the β7 
tail, whereas THD(L325R) exhibited a more modest reduction 
in affinity (Fig. S1, E and F). Both of these talin mutants abro-
gated the capacity of THD to increase the binding of soluble 
MAdCAM-1 to recombinant α4β7 (Figs. 1 G and S1, G and H). The 
effects of the mutations on soluble MAdCAM-1 binding were 
reflected by the reduction in adhesion (Fig. 1 H) and increased 
velocity of rolling (Fig. S1 I) on a MAdCAM-1 substrate. Notably, 
THD(L325R) expression reduced soluble MAdCAM-1 binding 
and increased rolling velocity relative to vector-transfected cells 
(Figs. 1 G and S1 I). This is ascribable to the dominant-negative 
effect of THD(L325R) competition with endogenous talin for 
binding to the β7 cytoplasmic domain. In sum, these data show 
that talin interacts with the β7 tail in a fashion analogous to β3 
and that, in doing so, it activates α4β7 to promote the arrest of 
rolling cells in flow.
Blocking talin-induced change in β7 TMD topology disrupts 
THD-induced integrin α4β7 activation
An α-β TMD association stabilizes the low-affinity state of αIIbβ3 
integrin (Li et al., 2002; Luo et al., 2004; Partridge et al., 2005), 
and talin binding disrupts this association, in part, by altering the 
topology of the β3 TMD, resulting in destabilization of the α-β TMD 
complex and integrin activation (Kim et al., 2012). To decouple 
talin-induced changes in inner β7 TMD topology from the outer 
half, we first aligned the TMD sequence of β3 and β7, and predicted 
that β7 Leu723 could correspond with β3 Ala711 (Fig. 2 A). Because 
the crossing angle of the β7 TMD is uncertain, we constructed a 
homology model of the structure of α4β7 TMD complex based on 
the αIIbβ3 TMD (Lau et al., 2008). Based on this model, we also 
selected Leu721 and Gly722 and mutated each of these three residues 
individually to proline and transfected 293T cells with the three 
mutants resulting in similar levels of expression to WT (Fig. S2 
A). Cells expressing either α4β7(L723P) or α4β7(L721P) exhibited 
markedly reduced adhesion to a MAdCAM-1 substrate at 2 dyn/
cm2 shear stress, whereas those expressing α4β7(G722P) exhibited 
a more mild reduction in adhesion (Fig. 2 B). The effect of the β7 
Pro mutations was largely mirrored in the marked reduction of 
binding of soluble MAdCAM-1 to cells expressing α4 in combina-
tion with either β7(L721P) or β7(L723P) and a lesser reduction for 
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Figure 1. Talin binding to the β7 cytoplasmic domain activates integrin α4β7. (A) Expression of talin and β7 in parental or talin KO β7-expressing Jurkat T 
cells. Top: Total expression by Western blot. Bottom: Surface expression by flow cytometry. The filled histograms represent untransfected Jurkat cells, whereas 
open histograms represent β7-expressing Jurkat cells or talin KO cells. (B) Binding of soluble MAdCAM-1 to β7 expressing Jurkat T cells or talin KO cells. PMA 
(100 nM) markedly increased binding to parental but not talin KO cells. Mn2+ (0.5 mM) stimulated binding to both cell types. Stimulated cells were compared 
with resting (None) for each cell line using one-way ANO VA. (C) Adhesion of β7-expressing Jurkat T cells or Jurkat-talin KO cells to MAdCAM-1 substrate in the 
presence or absence of PMA (100 nM) under a wall shear stress of 2 dyn/cm2. Nontransfected Jurkat T cells (Jurkat) provided a negative control. Jurkat-β7-Talin 
KO or Jurkat were compared with the Jurkat-β7 for each condition using one-way ANO VA. (D) Structural model of the talin F3 domain in complex with integrin 
β7 tail (Arg728 to Thr766). Talin F3 domain is shown by a surface representation and colored by charge. A ribbon diagram of the docked β7 tail is highlighted in 
red. β7-Leu758 and -Tyr759 in the NPLY motif are shown as light blue–colored stick figures. (E) Soluble MAdCAM-1 binding to 293T cells transfected with WT 
or mutant α4β7 with or without THD cotransfection. Mn2+ (0.5 mM) was used as a positive control for integrin activation. Nontransfected 293T cells (MOCK) 
provided a negative control. Mutant integrins were compared with the WT for each condition using one-way ANO VA. (F) Adhesion of 293T cells transfected with 
WT or mutant α4β7 with or without THD cotransfection on MAdCAM-1 under a wall shear stress of 2 dyn/cm2. Nontransfected 293T cells (MOCK) provided a 
negative control. Mutant integrins were compared with the WT for each condition using one-way ANO VA. (G) Binding of soluble MAdCAM-1 to 293T-α4β7 cells 
transfected with EGFP vector, EGFP-THD, EGFP-THD(L325R), or EGFP-THD(W359A). THD-stimulated cells were compared with vector control (α4β7 + EGFP 
vector) for each cell line using two-way ANO VA. MFI, mean fluorescent intensity. (H) Adhesion of 293T-α4β7 cells transfected with EGFP vector, EGFP-THD, 
EGFP-THD(L325R), or EGFP-THD(W359A) on MAdCAM-1 under a wall shear stress of 2 dyn/cm2. 293T cells transfected with THD only and nontransfected 293T 
cells (MOCK) were used as negative controls. THD-stimulated cells were compared with vector control (α4β7 + EGFP vector) for each cell line using one-way 
ANO VA. Error bars show means ± SD. n = 5. NS, P > 0.05; *, 0.01 < P < 0.05; **, 0.001 < P < 0.01; ***, P < 0.001. 
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α4β7(G722P) (Figs. 2 C and S2 B). Moreover, both of the leucine 
replacement mutants abolished the capacity of THD to increase 
soluble MAdCAM-1 binding (Fig. 2 C), and these results were mir-
rored in dramatically reduced effect of THD on adhesion (Fig. S2 C). 
However, cells expressing α4β7(G722P) showed only a mild reduc-
tion in THD-induced soluble MAdCAM-1 binding (Figs. 2 C and S2 
C). Notably, we found that the association of the THD with each of 
the mutant α4β7 integrins was similar to that observed with the 
WT integrin (Fig. 2 D). In addition, we also substituted Ala (non-
polar) or Gly (polar) for Leu721 and Leu723 and found they had no 
effects on α4β7 integrin-mediated adhesion to MAdCAM-1 with or 
without THD coexpression (Fig. S3). However, substitution Arg for 
Leu723 increased α4β7−mediated adhesion to MAdCAM-1. In sum, 
introduction of a proline but not other mutations at specific sites 
in the midpoint of the β7 TMD disrupts the capacity of talin to acti-
vate this integrin, without perturbing talin binding to the integrin, 
suggesting that a flexible kink in the β7 TMD blocks transmission 
of talin’s activation signal across the plasma membrane (Fig. 2 E).
Disrupting talin-induced change in β7 TMD topology blocks 
agonist-induced α4β7 activation
α4β7 is expressed primarily in lymphocytes and can be physio-
logically activated by chemokine stimulation (Wagner et al., 1996; 
Mora and Von Andrian, 2006; Agace, 2008; Gorfu et al., 2009). 
To assess whether a topological change in the β7 TMD is involved 
in agonist-induced activation of α4β7, we expressed β7(L721P) or 
β7(L723P) in Jurkat T cells that lack endogenous β7 expression. 
Jurkat cells lack chemokine receptors used in gut homing, CCR9 
and CCR7; hence, we used CXCL12 (SDF1α) to stimulate them via 
endogenous CXCR4. The proline mutants blocked the capacity of 
CXCL12 to increase the binding of soluble MAdCAM-1 (Fig. 3 A). 
Moreover, the Pro mutants also prevented activation by the 
receptor-independent agonist PMA. The direct integrin activator 
Mn2+ enhanced the binding of MAdCAM-1 to cells bearing either 
Pro mutant (Fig. 3 A), consistent with the fact that the mutant and 
WT integrins were expressed at similar abundance on the cell 
surface (Fig. 3 B). In addition, similar quantities of endogenous 
Figure 2. Blocking talin-induced change in 
β7 TMD topology abolished α4β7 activation. 
(A) Sequence alignment of partial TMDs of inte-
grin β3 and β7 subunits. β3 Pro mutant site Ala711 
is highlighted in red. The sites in β7 that were 
mutated to Pro (Leu721 and Leu723) are highlighted 
in green and Gly722 is highlighted in pink and are 
projected onto a homology model of the α4β7 
TMD (α4 in blue and β7 in red). (B) Adhesion of 
293T cells transfected with β7 WT or mutations 
(L721P, G722P, or L723P) plus α4 on MAdCAM-1 
under a wall shear stress of 2 dyn/cm2. Non-
transfected 293T cells (MOCK) were used as a 
negative control (Ctrl). Mutant integrins were 
compared with the WT using one-way ANO VA. 
(C) Binding of soluble MAdCAM-1 to 293T cells 
transfected with WT α4β7 or α4 in combination 
with mutants (L721P, G722P, and L723P) in the 
presence or absence of THD. Nontransfected 
293T cells (MOCK) were used as a negative con-
trol. Mutant integrins were compared with the 
WT for each condition using one-way ANO VA. 
Error bars show means ± SD. n = 5 (A and B) or 4 
(C). *, 0.01 < P < 0.05; **, 0.001 < P < 0.01; ***, 
P < 0.001. MFI, mean fluorescence intensity. (D) 
Coimmunoprecipitation of THD with α4β7 WT or 
mutants. Lysates of 293T cells were transfected 
as in C, in combination with THD-GFP, and α4β7 
was isolated by immunoprecipitation (IP). Pre-
cipitated proteins were analyzed by Western 
blotting with the indicated antibodies and con-
firmed similar THD association with the mutant 
and WT integrins. Data are representative of at 
least three independent experiments. Note that 
a shorter exposure time was used for the THD 
input. Molecular masses are given in kilodaltons. 
(E) A model of how a Pro mutation can prevent 
transmission of altered topology of the β7 TMD 
by talin. The complex formed between the β7 
cytoplasmic tail/TMD (red) and cytoplasmic talin 
F3 domain (surface representation; colored by 
charge) alters the topology of the inner portion of the transmembrane helix, which is transmitted to the outer moiety, where it can disrupt the outer membrane 
clasp (Lau et al., 2009), resulting in destabilization of the α-β TMD complex and integrin activation. β7(L721P) breaks the TMD helix into two helices connected 
by a flexible kink; the flexible kink prevents transmission of the talin-induced change in intracellular TMD topology to stabilize the α-β TMD interaction and 
block talin-induced activation of integrin α4β7.
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talin and kindlin 3 were associated with the mutant and WT 
α4β7 in both resting and chemokine-stimulated Jurkat T cells 
(Fig. 3 C). In the flow chamber, which mimics the interaction of 
T cells with endothelial MAdCAM-1 in flowing blood, the proline 
mutants blocked the capacity of both CXCL12 and PMA to induce 
the arrest of rolling T cells (Fig. 4, A and B). The suppression of 
α4β7 activation was also mirrored by the marked increase in roll-
ing velocity of stimulated T cells bearing either proline mutant 
(Fig. 4, C and D; and Fig. S4 A). Similar results were obtained in 
the static cell adhesion experiments. CXCL12 treatment markedly 
enhanced the adhesion of WT β7 cells on MAdCAM-1. In contrast, 
the cells bearing β7(L721P) or β7(L723P) did not exhibit CXCL12 
stimulation of α4β7-mediated adhesion to MAdCAM-1 (Fig. S4 
B). Thus, blocking TMD transmission of talin-mediated topology 
change impaired the capacity of physiological agonists to pro-
mote α4β7-mediated arrest of rolling T cells.
β7(L721P) mutation inhibits lymphocyte homing to GALT
The foregoing studies established the importance of the chang-
ing topology of the β7 subunit TMD in talin-induced α4β7 acti-
vation in vitro. To examine its importance in the physiological 
function of α4β7 integrin, we introduced this mutation into 
TK1 mouse T cells that express α4β7 (Rüegg et al., 1992; Berlin 
et al., 1993). We first used CRI SPR/Cas9 mutagenesis to generate 
β7-null TK1 clones. We then used lentivirus-mediated transduc-
tion to express β7 and β7(L721P) at similar levels in these TK1-
β7-KO cells (Fig. 5 A). We examined the capacity of these TK1 cell 
lines to bind to soluble MAdCAM-1 in the presence or absence 
of CXCL12 stimulation (Fig. 5 B). The cells expressing β7(L721P) 
bound negligible soluble MAdCAM-1 in the presence or absence 
of CXCL12. In contrast, both β7-expressing TK1-β7–null cells 
and WT TK1 cells bound MAdCAM-1, and binding was markedly 
increased by CXCL12 stimulation. The capacity of Mn2+ to stim-
ulate MAdCAM-1 binding to β7(L721P) cells confirmed that this 
mutation did not disrupt the ability of the integrin to bind ligand, 
but only prevented the transmission of signaling events that led 
to activation.
To examine the effect of the Pro mutation on lymphocyte 
homing, TK1-β7–null cells expressing either β7 WT or β7 proline 
mutation (β7[L721P]) cells were labeled with eFluor 670 or car-
boxyfluorescein succinimidyl ester (CFSE), respectively. Equal 
numbers (2 × 107) of eFluor 670–labeled cells and CFSE-labeled 
cells were mixed and then injected intravenously into C57BL/6J 
mice. The number of eFluor 670– or CFSE-labeled cells in mes-
enteric lymph node (MLN), Peyer's patch (PP), peripheral lymph 
node (PLN), and spleen (SP) were enumerated by flow cytome-
try. A homing index, defined as the ratio of TK1-β7 WT or TK1-
β7(L721P) to TK1 cells, was determined. Compared with TK1 
cells, TK1-β7 WT cells homed equally well to MLN, PP, PLN, and 
SP (Fig. 5, C and D). In contrast, TK1-β7(L721P) cells homing to 
PP were dramatically reduced. Homing to MLN was also sig-
nificantly reduced, albeit to a lesser extent than PP. In contrast, 
TK1-β7(L721P) cells homing to PLN and SP were similar to TK1-β7 
WT and TK1 cells (Fig. 5, C and D). Thus, blocking talin-induced 
change in β7 TMD topology impaired the capacity of α4β7 to 
mediate lymphocyte homing to GALT.
Figure 3. Inhibiting talin-induced change in 
β7 TMD topology impairs agonist-induced 
α4β7 activation. (A) Binding of soluble MAd-
CAM-1 to Jurkat T cells stably expressing WT 
or mutant β7(L721P or L723P) with or without 
CXCL12 or PMA stimulation. Mutant integrins 
were compared with the WT for each condition 
using one-way ANO VA. Error bars show means 
± SD. n = 5. NS, P > 0.05; **, 0.001 < P < 0.01; 
***, P < 0.001. MFI, mean fluorescence intensity. 
(B) β7 cell surface expression on Jurkat T cells sta-
bly expressing WT or mutant β7(L721P or L723P). 
Mock-transfected cells are depicted in the filled 
histograms. (C) α4β7 was immunoprecipitated 
(IP) from lysates of CXCL12-stimulated cells or 
unstimulated cells depicted in A, and bound pro-
teins were analyzed by Western blotting with the 
indicated antibodies. Data are representative of 
at least three independent experiments. Molec-
ular masses are given in kilodaltons.
Sun et al. 
Transmembrane topology and integrin function
Journal of Cell Biology
https://doi.org/10.1083/jcb.201707055
1458
β7(L720P) mutation disrupts GALT development
To examine the role of the topology of the β7 TMD in development 
of GALT, we analyzed mice bearing β7(L720P) (homologous to 
human β7[L721P]) mutation. CRI SPR/Cas9 mutagenesis was used 
to generate four male founder Itgb7L720P/L720P mice (Fig. 6, A and 
B) who were then crossed with C57BL/6J females. Itgb7L720P/WT 
male F1 mice were backcrossed to C57BL/6J females, and the Itg-
b7L720P/WT F2 mice were intercrossed to generate Itgb7L720P/L720P 
and WT littermates for comparison. Itgb7L720P/L720P mice were 
born at expected Mendelian ratios and were apparently healthy. 
Moreover, normal numbers of both T and B cells were present in 
the secondary lymphoid organs such as SP and PLNs (Fig. 6 C). 
In sharp contrast, there was a profound reduction in both cell 
types in the PPs and a lesser reduction in MLNs consistent with 
the defect in lymphocyte homing to these sites. The percentage 
of CD4 and CD8 cells in Itgb7L720P/L720P mice was similar to the WT 
mice (Fig. S5 A). Furthermore, the localization within lymphoid 
organs of CD4 T cells, CD8 T cells, B cells, macrophages, and den-
dritic cells in Itgb7L720P/L720P mice was not grossly different from 
WT mice (Fig. S5, B and C). Thus, this proline mutation in the 
central β7 TMD disrupts development of the GALT.
Previous research demonstrated that integrin α4β7 is con-
stitutively expressed on naive T and B cells at a relatively low 
level (Erle et al., 1994), and retinoic acid, produced by gut den-
dritic cells, enhances the expression of α4β7 on CD4+ T cells to 
imprint them with the gut tropic α4β7high phenotype (Gorfu 
et al., 2009). Thus, we speculated the β7 proline mutation, by 
preventing contact with gut dendritic cells during maturation, 
might reduce β7 expression in adult T cells. To avoid potential 
effects of postpartum lymphocyte cell education, we tested the 
surface expression of integrin αL, α4, β1, β2, and β7 as well as 
intracellular expression of kindlin 3 (FER MT3) and talin (TLN) 
in neonatal mice (Fig. 7 A). The expression of those integrins 
and integrin intracellular binding proteins was similar in both 
WT mice and Itgb7L720P/L720P mice. In contrast, lymphocyte α4β7 
expression was decreased in adult Itgb7L720P/L720P mice (Fig. 7 B). 
To test the idea that the effector/memory T cells might be selec-
tively affected, we compared β7 surface expression on naive T 
cells (CD62LhighCD44low) and effector T cells (CD62LlowCD44high) 
in adult WT and Itgb7L720P/L720P mice (Fig. 7 C). As expected, in WT 
mice, β7 expression was increased twofold in effector/memory 
compared with naive T cells. In sharp contrast, Itgb7L720P/L720P 
effector/memory T cells exhibited similar β7 expression to 
naive T cells.
Discussion
The concept of “inside-out signal transduction” was engendered 
by the capacity of signals generated within cells to regulate 
the affinity and functioning of integrin extracellular domains 
(Ginsberg et al., 1992), and research with platelet integrin αIIbβ3 
has played a central role in a current model of the process. One 
model proposes that talin, by binding to the β3 integrin cytoplas-
mic domain, disrupts an electrostatic interaction that strength-
ens the inner membrane clasp that stabilizes the αIIbβ3 TMD 
association. Changes the topology of the β TMD disrupt an outer 
membrane clasp to complete the activation process (Kim et al., 
2011). Recent research has indicated marked differences in the 
mechanism of inside-out activation of other classes of integrins 
(Lu et al., 2016). In this study, we have tested the talin-induced 
topology change model with a leukocyte integrin, α4β7. We find 
that introduction of proline, known to form a flexible kink in an 
integrin β TMD, blocks talin-induced inside-out integrin signal-
ing and biological functions in development. These studies estab-
lish, in a physiological setting, the importance of transmission of 
β subunit TMD topology across the membrane.
Figure 4. Blocking TMD topology transmission in β7 
impaired agonist-promoted arrest of rolling T cells. (A and 
B) Adhesion of Jurkat T cells that stably expressed WT or mutant 
β7(L721P or L723P) on MAdCAM-1 with or without CXCL12 (A) 
or PMA (B) stimulation under a wall shear stress of 2 dyn/cm2. 
Mutant integrins were compared with the WT for each condi-
tion using one-way ANO VA. (C and D) Rolling velocity of Jurkat 
T cells that stably expressed WT or mutant β7(L721P or L723P) 
on MAdCAM-1 with or without CXCL12 (C) or PMA (D) stimu-
lation under a wall shear stress of 2 dyn/cm2. Stimulated cells 
were compared with resting (None) for each cell line using one-
way ANO VA. The numbers of cells remaining bound (A) and cell 
velocity (B) were analyzed. Error bars show means ± SD. n = 5. 
NS, P > 0.05; ***, P < 0.001.
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Activation of integrin α4β7 is mediated by talin binding 
to the β7 cytoplasmic domain in a mechanism analogous to 
αIIbβ3. Talin deletion in T cells reduced but did not eliminate 
the α4β7-mediated constitutive binding of and adhesion to 
MAdCAM-1, whereas lack of talin virtually eliminated the PMA- 
induced increase in MAdCAM-1 interactions. Thus, as with β1, 
β2, and β3 integrins, talin is required for agonist-induced activa-
tion, defined as an increase of ligand binding affinity above a low 
constitutive level. These effects of talin deletion were mirrored 
by the effects of β7 mutations that disrupt talin binding, showing 
that the interaction of talin with β7 is required as it is with β1 
and β3 integrins (Tadokoro et al., 2003). Similarly, talin mutants 
that block binding to the membrane proximal or membrane dis-
tal sites in β3 (Wegener et al., 2007) both impaired the capacity of 
THD to activate α4β7, indicating that talin binding activates α4β7 
through a similar mechanism to αIIbβ3.
The integrin β TMD transmits talin-induced altered TMD 
topology to the extracellular domain to activate integrins and 
mediate their biological functions. Introduction of a proline 
residue in the β7 TMD impaired activation of α4β7. The effect of 
the proline cannot be ascribed to simple replacement of a hydro-
phobic leucine because substitution with other neutral residues, 
e.g., alanine, did not have this effect. Rather, it is the capacity to 
introduce a flexible kink in the TMD (von Heijne, 1991; Nilsson 
and von Heijne, 1998; Visiers et al., 2000; Kim et al., 2011) that 
accounts for this unique property of proline. The effect of this 
flexible kink is to reduce helix rigidity, thereby decoupling a 
physical displacement of the inner half of the TMD from the 
outer half (Kim et al., 2012), thus preserving the outer membrane 
clasp. The location of the proline was relevant in that placing the 
proline in place of Gly722 had a weaker effect. The increased flex-
ibility provided by proline insertions can limit the transmission 
Figure 5. Suppressing talin-induced change in 
β7 TMD topology perturbed mouse lymphocyte 
homing to the gut. (A) Cell surface expression of 
α4β7 in TK1-β7 KO cells stably expressing WT β7 
or mutant β7(L721P). (B) Binding of soluble mouse 
MAdCAM-1 to the cells shown in A with or without 
CXCL12 stimulation. The TK1-β7 KO cell was used as 
a negative control. Stimulated cells were compared 
with resting (None) for each cell line using one-way 
ANO VA. MFI, mean fluorescence intensity. (C and 
D) In vivo competitive homing of TK1-β7 KO cells 
that stably express WT β7(β7 WT) or proline mutant 
β7(β7[L721P]) to different lymphoid tissues. TK1-β7 
WT or TK1-β7(L721P) cells were labeled with eFluor 
670. TK1 parental (TK1) cells were labeled with CFSE 
as an input control. Equal numbers (2 × 107) of eFluor 
670–labeled cells and CFSE-labeled cells were mixed 
and then intravenously injected into C57BL/6J mice. 
Lymphoid organs were isolated 2 h after injection. 
The eFluor 670– or CFSE-labeled cells that homed 
into different lymphoid organs were enumerated by 
flow cytometry. The total numbers of homed cells 
to different lymphoid organs are shown in C. MLN 
(per mouse), PP (per mouse), PLN (per lymph node), 
and SP (per mouse). The ratio of TK1 parental cells to 
TK1-KO cells reconstituted with β7 WT or β7(L721P) 
cells recovered from different lymphoid organs is 
shown in D. Error bars show means ± SD. n = 5 (A 
and B) or 24 (C and D). NS, P > 0.05; **, 0.001 < P < 
0.01; ***, P < 0.001. 
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of talin-induced change in topology of the inner to the outer half 
of the β TMD domain, thereby stabilizing the α-β transmembrane 
helix association by preserving the helical packing required to 
form the outer membrane clasp.
Our research provides new insight into how α4β7 mediates 
formation of the mucosal immune system and suggests new ther-
apeutic approaches. The role of β7 integrins in assembly of the 
mucosal immune system has long been known (Wagner et al., 
1996; Gorfu et al., 2009; Villablanca et al., 2011) as has the role 
of chemokine stimulation of those cells (Gorfu et al., 2009; Sun 
et al., 2014) that activates integrin α4β7; however, direct proof 
of an integrin activation requirement by itself for development 
is lacking. Our research is the first to establish the importance 
of integrin activation as the key effect of chemokine stimulation 
in homing and development. The pathogenesis of IBD involves a 
massive influx of immune cells into the gastrointestinal mucosa 
(Adams and Eksteen, 2006; Eksteen et al., 2008; Villablanca 
et al., 2011) with infiltration of inflammatory lymphocytes in 
the colonic lamina propria of IBD patients (Caradonna et al., 
2000; Smith et al., 2005). Vedolizumab, a mAb that blocks α4β7 
function, has been approved for the treatment of IBD in adults 
(McLean et al., 2012; Poole, 2014; Cherry et al., 2015); however, 
the extent to which it shares the risk of progressive multifocal 
leukoencephalopathy induced by anti-α4β1 antibodies is uncer-
tain (Lam and Bressler, 2014). Moreover, aggravated colitis is 
observed in a small percentage of patients treated with high 
dose of vedolizumab (Feagan et al., 2005; Rutgeerts et al., 2013). 
As shown in this study, blockade of talin-induced activation 
preserves some α4β7 adhesive function, in contrast with full 
blockade with antibodies such as vedolizumab. Thus, blockade 
of activation may avert mechanism-based toxicities while pre-
serving a therapeutic effect. In this study, we add to a deeper 
understanding of the signaling events that control α4β7 activa-
tion and development of the GALT, which may ultimately lead to 
new strategies for treating IBD or other α4β7 integrin-mediated 
pathologies such as HIV-AIDS.
Figure 6. Disruption of GALT development in Itgb7L720P/L720P mice. (A) Schematic of the Cas9/sgRNA-targeting sites in Itgb7. The sgRNA-targeting sequences 
are underlined in blue, and the protospacer-adjacent motif (PAM) sequence is labeled in blue in the WT sequence. The MaeI restriction site removed from the 
WT and ApaI site introduced in the mutant are labeled as are the Leu codon changed to Pro. (B) Sequencing analysis of WT and β7(L720P) knock-in mice. DNA 
sequencing confirmed a leucine to proline substitution at position 720 of the mouse β7 integrin gene (position 721 in human β7 integrin gene). The mutation 
is labeled in red. The silent mutations are labeled in green and with green asterisks. (C) The absolute number of CD3+ T cells and B220+ B cells isolated from 
Itgb7WT/WT mice and Itgb7WT/L720P, or Itgb7L720P/L720P littermates are shown. Error bars show means ± SD. n = 8. NS, P > 0.05; ***, P < 0.001. 
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Materials and methods
cDNAs and recombinant proteins
A modified pET-15b vector encoding a His6-AviTag at the N ter-
minus of the integrin cytoplasmic tail was used as a recombi-
nant model protein affinity matrix as previously described (Pfaff 
et al., 1998). cDNA encoding integrin β7 (730–779) cytoplasmic 
tails, WT, β7(L758A), and β7(Y759A) were cloned into this vector, 
replacing the αIIb tail sequence, and recombinant model proteins 
were produced as described previously (Gingras et al., 2012). The 
cDNAs encoding the mouse THD (residues 1–400) WT, L325R, 
and W359A were cloned into pEGFP-C1 vector. The cDNAs encod-
ing the full-length human α4, β7, and mouse β7 proteins were 
amplified by RT-PCR and cloned into pCDNA3.1 or pLVX lentiviral 
expression vector. Cloning of β7 point mutants (L758A, Y759A, 
L721P, G722P, and L723P) was done by oligonucleotide-directed 
mutagenesis using the Infusion-HD Eco Dry cloning kit (Takara 
Bio Inc.). The cDNAs encoding the ectodomain of human and 
mouse MAdCAM-1 proteins were amplified by RT-PCR and fused 
to a cDNA encoding an IgG Fc fragment into pCDNA3.1. Recom-
binant MAdCAM-1 (Val1 to Pro315) fused to the Fc2/3 regions of 
human IgG1 was produced in pcDNA3.0 (Invitrogen) and purified 
by Protein A resin (GenScript) as described previously (Sun et al., 
2011). Mouse β7 and human talin single guide RNAs (sgRNAs) 
were constructed in vector pSpCas9n(BB)-2A-Puro (48141; 
Addgene; Ran et al., 2013). The sgRNA sequences were as follows: 
β7-sgRNA1, 5′-GCA TCG TGG CAG TGG GAC TAGGG-3′; β7-sgRNA2, 
5′-CGT GGC AGT GGG ACT AGG GCTGG-3′; and talin-sgRNA, 5′-ACC 
TGA CGG AGA TGT CCC GTGGG-3′ (protospacer-adjacent motif 
sequences are underlined). All constructs were confirmed by 
DNA sequencing.
Cell culture experiments
293T, Jurkat, and TK1 cells were purchased from ATCC. 293T cells 
transiently expressing α4 and β7 WT and mutants were gener-
ated by Lipofectamine 3000 transfection (Invitrogen). Jurkat T 
cells that stably expressed WT and mutant β7 were generated 
by lentiviral transduction followed by selection with puromycin 
and cell sorting. WT or mutant β7-expressing lentiviral particles 
were prepared by cotransfection of pLVX-WT β7, β7(L721P), or 
β7(L723P) with pMDLg/pRRE, pRSV-Rev, and pMD2.G in 293T 
cells. Supernatants containing lentiviral particles were col-
lected. For lentiviral delivery, Jurkat T cells were grown to 80% 
confluence and then infected with pLVX-WT β7–, β7(L721P)–, 
or β7(L723P)–containing lentiviral particles. Cells were then 
selected with puromycin (2 µg/ml) 72 h after infection.
To make TK1-β7 KO cells, TK1 cells were cotransfected with 
β7-sgRNA1 and 2 and Cas9-EGFP using an Amaxa electropora-
tor (Lonza) followed by cell sorting of EGFP-positive cells. 5–7 d 
later, the TK1-β7 KO cells were incubated with anti-β7 antibody, 
and β7-null cells were isolated as unbound to anti–rabbit IgG 
MicroBeads (Miltenyi Biotech). The TK1-β7 KO cells were recon-
stituted with β7 or β7(L721P) by lentiviral transduction followed 
by selection with puromycin and FACS sorting for similar β7 
expression. Cells were routinely tested for mycoplasma infec-
tion. To generate the Jurkat–talin KO cells, cells were transfected 
with pSpCas9(BB)-2A-EGFP vector expressing the sgRNA (5′-ACC 
TGA CGG AGA TGT CCC GTGGG-3′; protospacer-adjacent motifs are 
underlined) using an Amaxa electroporator (Lonza). 48 h later, 
EGFP-positive cells were single-cell cloned by automated cell 
deposition unit using a FAC SAria (BD), and cells lacking talin 1 
and talin 2 were selected by immunoblotting with an antibody 
that recognizes both forms of talin (Fig. 1 A).
Antibodies and reagents
The following antibodies were purchased from BioLegend: 
CD4 (GK1.5), CD8 (53–6.7), CD44 (1M7), CD62L (MEL-14), 
B220 (RA3-6B2), CD11c (N418), and F4/80 (BM8). Monoclonal 
anti-GFP (1:5,000; Takara Bio Inc.), monoclonal anti–β-actin 
(1:5,000; Sigma-Aldrich), monoclonal anti–human β7 (EPR1357, 
1:3,000; Abcam), monoclonal antitalin (8d4, 1:1,000; Sigma- 
Aldrich), and polyclonal anti–kindlin 3 antibody (1:500; Abgent; 
Ye et al., 2013) were used for immunoblotting. FIB504 against 
human/mouse β7 prepared by using hybridoma cells was used 
for immunofluorescence at 2 µg/ml. Act-1 against human α4β7 
was used for immunoprecipitation as previously described 
(Sun et al., 2011). Secondary Alexa Fluor–labeled antibodies for 
Western blot analysis were from Rockland or Thermo Fisher 
Scientific. CFSE and eFluor 670 were purchased from Invitro-
gen and BioLegend, respectively. Human and mouse CXCL12 
Figure 7. Itgb7L720P/L720Padult mice have reduced gut-tropic β7high effector/
activated T cells. (A) Equivalent cell surface expression of integrin αL, α4, β1, β2, 
and β7 and intracellular expression of kindlin 3 and talin in neonatal Itgb7WT/WT 
mice and Itgb7L720P/L720P littermates are shown. (B) Cell surface expression of 
β7 is reduced in 8-wk-old Itgb7L720P/L720P compared with Itgb7WT/WT littermates. 
(C) The ratio of cell surface expression of integrin β7 on effector/activated T cells 
(CD62LlowCD44high) compared with naive T cells (CD62LhighCD44low) in 8-wk-old 
Itgb7WT/WT mice and Itgb7L720P/L720P littermates. Mean fluorescence intensities 
are displayed on the representative histograms. Error bars show means ± SD. 
**, 0.001 < P < 0.01. Teff, effector T cells.
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were purchased from R&D Systems. PMA was purchased from 
Sigma-Aldrich. 
Mice
All animal experiments were approved by the Institutional 
Animal Care and Use Committee of the University of Califor-
nia, San Diego. All mice were housed in specific pathogen-free 
conditions before use. The Itgb7L720P/L720P knock-in mice were 
generated using the CRI SPR/Cas9 approach by the Transgenic 
Mouse Facility of the University of California, Irvine. B6SJL 
female mice were used as embryo donors. Single-stranded 
oligodeoxynucleotide (ssODN) was used as a homology-di-
rected repair template and purchased from Integrated DNA 
Technologies as Ultramer DNA oligonucleotides. ssODN was 
mixed with Cas9 mRNA and sgRNA directly without purifica-
tion. The sequence of ssODN was 5′-GTC AGC CCT TAA ACC TTG 
GCC CCA CCA GAG GGA GTG GAT CAC ACC CGT GCC ATC ATA CTG 
GGC TGC ACA GGG GGC ATC GTG GCA GTG GGC CCA GGC CTC GTT 
CTG GCT TAC CGG CTC TCT GTG GAA ATC-3′. Mononuclear cells 
were isolated from SP, peripheral blood, PLN, MLN, and PP by 
tissue homogenizer (JXF STP RP-24; ThunderSci) as previously 
described (Berlin et al., 1995; Sun et al., 2014). Cell counting 
with immunofluorescence cytometry was performed using 
Accuri C6 FAC SCalibur (BD).
Flow cytometry
5 × 106 cells were washed and resuspended in HBSS containing 
0.1% BSA and 1 mM Ca2+/Mg2+ and stained with allophycocy-
anin (APC) anti–human/mouse integrin β7 antibody (1:500; 
FIB504; BioLegend) for 30 min at 4°C. APC rat IgG2a was used 
as isotype control. Cells were washed twice before flow cytom-
etry analysis using a FAC SCalibur. Data were analyzed with 
FlowJo software.
For the soluble ligand binding assay, after treating with Fc 
receptor blocking (BioLegend) to reduce nonspecific binding, 
5 × 106 cells were washed and resuspended in HBSS containing 
0.1% BSA and 1 mM Ca2+/Mg2+. The MAdCAM-1/Fc fusion protein 
was added to the mixture and incubated for 30 min at room tem-
perature with or without PMA (100 nM for 30 min) or CXCL12 
(0.5 µg/ml for 2 min). Then cells were immediately fixed by 2% 
paraformaldehyde at room temperature for 15 min followed by 
two washes and then incubated with Alexa Fluor 647–conjugated 
anti–human IgG (1:1,000) for 30 min at 4°C.
Affinity chromatography with recombinant integrin 
cytoplasmic domains
Cells were lysed with cold cell lysis buffer (50  mM Tris-HCl, 
pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1% NP-40, and 10% glyc-
erol) plus protease inhibitor cocktails (Roche) on ice for 30 min. 
Affinity chromatography was performed using recombinant 
His-Avi-integrin cytoplasmic domain model proteins bound 
to NeutrAvidin resin (Novagen) as previously described (Pfaff 
et al., 1998; Petrich et al., 2007a). Samples were separated on a 
4–20% SDS polyacrylamide gel (Novex; Invitrogen). Bound THD 
was stained by monoclonal anti-GFP (1:5,000; Takara Bio Inc.) 
and detected and quantified using an Odyssey imaging system 
(LI-COR Biosciences).
Flow chamber assay
The assembly of the microfluidic devices used in this study has 
been described previously (Fan et al., 2016). In brief, covers-
lips were coated with MAdCAM-1/Fc (10 µg/ml) alone or with 
CXCL12 (2 µg/ml) for 1 h and then blocked for 1 h with casein 
(1%) at room temperature. After coating, coverslips were sealed 
to polydimethylsiloxane chips by magnetic clamps to create flow 
chamber channels ∼29 µm high and ∼300 µm across. By modu-
lating the pressure between the inlet well and the outlet reser-
voir, 2 dyn/cm wall shear stress was applied in all experiments. 
Cells were diluted to 5 × 106 cells/ml in HBSS (with 1 mM Ca2+/
Mg2+) and immediately perfused through the flow chamber. For 
the PMA stimulation, cells were prestimulated for 10 min with 
PMA (100 nM) at room temperature before perfusion.
Adhesive interactions between the flowing cells and the 
coated substrates were assessed by manually tracking the 
motions of individual cells for 1 min as previously described (Sun 
et al., 2014). The motion of each adherent cell was monitored for 
10 s after the initial adhesion point, and two categories of cell 
adhesion were defined: rolling adhesion cells had rolling motions 
for >10 s with a velocity >1 µm/s, whereas cells that remained 
adherent and stationary for >10 s with a velocity <1 µm/s were 
defined as arrested adherent cells.
Static adhesion assay
Wells of a 96-well Immulon 2HB (Thermo Fisher Scientific) 
plate were coated overnight at 4°C with MAdCAM-1/Fc (10 µg/
ml) with or without CXCL12 (2 µg/ml) in coating buffer (PBS and 
10 mM NaHCO3, pH 9.0). After the plates were rinsed with PBS, 
free binding sites were blocked with 2% BSA in coating buffer 
for 1 h at 37°C. Serum-starved Jurkat T cells were then added to 
wells and were allowed to adhere for 2 h at 37°C. Plates were then 
washed with PBS, and bound cells were stained with crystal vio-
let (1%) after fixation with 3.7% formaldehyde.
Immunoprecipitation and blotting
Cells were lysed with ice-cold cell lysis buffer (50 mM Tris-HCl, 
pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1% NP-40, and 10% glyc-
erol) plus protease inhibitor cocktails (Roche) on ice for 30 min 
and immunoprecipitated with the α4β7 mAb, Act-1 (1 µg). Mouse 
IgG was used as a control. After overnight incubation with anti-
bodies at 4°C, Protein G Sepharose (Invitrogen) was added to the 
reaction mixture and further incubated for 2–4 h at 4°C. After 
three washes with ice-cold lysis buffer, beads were mixed with 
sample buffer before separation on a 4–20% SDS polyacryl-
amide gel (Novex; Invitrogen). Western blots were stained with 
monoclonal anti–human β7 (EPR1357, 1:3,000; Abcam), mono-
clonal antitalin (8d4; 1:1,000; Sigma-Aldrich), and monoclo-
nal anti–β-actin (1:5,000; Sigma-Aldrich). Signal was detected 
and results were quantified using an Odyssey imaging system 
(LI-COR Biosciences).
In vivo competitive lymphocyte homing
TK1-β7 WT or TK1-β7(L721P) cells were labeled with eFluor 670 
(eBioscience), and TK1 cells were labeled with CFSE (BioLeg-
end). Equal numbers (5 × 107) of eFluor 670–labeled cells and 
CFSE-labeled cells were mixed and then injected into the tail 
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vein of recipient C57BL/6J mice. After 2  h, the recipient mice 
were sacrificed, and lymphocytes from MLN, PP, PLN, and SP 
were harvested. The absolute cell numbers were calculated by 
measuring the ratio of CFSE- and eFluor 670–labeled cells by 
flow cytometry and then adjusted to the total cell count (hemo-
cytometer). All animal experiments were approved by the Uni-
versity of California, San Diego, Institutional Animal Care and 
Use Committee in adherence with National Institutes of Health 
guidelines and policies.
Immunofluorescence staining
Mice frozen lymphoid organ sections were fixed with 4% PFA for 
10 min at room temperature and blocked with 5% FBS plus 5% rat 
serum for 1 h at room temperature. Then the section was stained 
with either 2.5 µg/ml of CD8 (53–6.7) Alexa Fluor 594, 2.5 µg/ml 
of CD4 (GK1.5) Alexa Fluor 647, and 2.5 µg/ml of B220 (RA3-6B2) 
Alexa Fluor 488, or 2.5 µg/ml of F4/80 (BM8) Alexa Fluor 647 and 
2.5 µg/ml of CD11c (N418) Alexa Fluor 488 overnight at 4°C. All 
antibodies were purchased from BioLegend.
Images were acquired using a Keyence BZX-700 all-in-one 
fluorescence microscope with CFI Plan Apochromat λ4× fluores-
cent objective (Nikon Plan Apochromat; 0.2 NA) or CFI Plan Apo-
chromat λ10× fluorescent objective (Nikon Plan Apochromat; 
0.45 NA), which was operated with a 2/3-in, 2.83 million pixel 
monochrome charge-coupled device colorized with a liquid chro-
matography filter at 25°C. Fluorochromes used for these analyses 
were Alexa Fluor 594, Alexa Fluor 647, Alexa Fluor 488, and/or 
DAPI. Images were processed and analyzed by a BZ-II Analyzer 
(Keyence) and Photoshop Element 10 software (Adobe). Back-
ground was reduced using brightness and contrast adjustments 
applied to the whole image.
Statistical analysis
Statistical analysis was performed in PRI SM software (6.00; 
GraphPad Software), and all datasets were checked for Gauss-
ian normality distribution. Data analysis was performed using 
one-way ANO VA or two-way ANO VA with Bonferroni’s post 
hoc test as indicated in figure legends. The resulting p-values 
are indicated as follows: NS, P > 0.05; *, 0.01 < P < 0.05; **, 
0.001 < P < 0.01; ***, P < 0.001. Data represent means ± SD or 
SEM of at least three independent experiments. Western blot 
results show representative images from at least three indepen-
dent experiments.
Online supplemental material
Fig. S1 confirms that talin-mediated α4β7 activation required spe-
cific contacts between the β7 region and talin F3. Fig. S2 confirms 
that changed β7 TMD topology mediates α4β7 activation. Fig. S3 
shows that introduction of Ala, Gly, or Arg residues instead Pro 
at the midpoint of the β7 TMD had no effects on α4β7 activation 
by THD. Fig. S4 confirms that disrupting talin-induced change 
in β7 TMD topology impaired CXCL12-mediated α4β7 activation. 
Fig. S5 shows the organization of lymph nodes and the distribu-
tion and localization of different cell types in 8-wk-old Itgb7WT/WT 
mice and Itgb7L720P/L720P littermates.
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